Anika Therapeutics Inc (ANIK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $173.07M
Last updated: Nov 17, 2026 at 4:15 PM ET
Anika Therapeutics Inc (ANIK) Statistics
Anika Therapeutics (ANIK) has a market cap of $173.07M and an enterprise value of $128.11M. Its share count is down 7.15% from a year earlier. It holds $44.96M more cash than debt, 25.98% of its market cap.
Total Valuation
Enterprise value is 25.98% below the market cap, as cash exceeds debt.
| Market Cap | $173.07M |
|---|---|
| Enterprise Value | $128.11M |
| Latest price (Nov 17, 2026) | $12.85 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.4x and 1.3x. Its year-end P/E ranged from 22.8x to 63.7x from 2016 to 2020.
| P/E Ratio | 18.6x |
|---|---|
| Forward P/E | 359.9x |
| P/S Ratio | 1.4x |
| Forward P/S | 1.4x |
| P/B Ratio | 1.3x |
| P/TBV Ratio | 1.3x |
| P/FCF Ratio | 75.0x |
| P/OCF Ratio | 23.1x |
Enterprise Valuation
Counting debt and cash, the company is valued at 41.4x EBITDA and 55.4x free cash flow.
| EV / Sales | 1.0x |
|---|---|
| EV / EBITDA | 41.4x |
| EV / FCF | 55.4x |
Price Statistics
The stock is up 28.63% over 52 weeks and trades 33.52% below its 50-day average.
| Beta (1Y) | 0.71 |
|---|---|
| 52-Week Change | +28.63% |
| 1-Month Change | -36.45% |
| 3-Month Change | -39.56% |
| 6-Month Change | -13.29% |
| 5-Year Change | -49.70% |
| 10-Year Change | -52.77% |
| Total Return (1Y) | +28.63% |
| Total Return (3Y CAGR) | -15.10% |
| Total Return (5Y CAGR) | -20.55% |
| Return vs SPY (1Y) | +21.33% |
| Max Drawdown (1Y) | -41.67% |
| Max Drawdown (3Y) | -71.83% |
| Sharpe Ratio (1Y) | 0.49 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $19.33 |
| 200-Day Average | $16.45 |
| 52-Week Range | $9.01 to $22.88 |
| RSI (14 Days) | 22.3 |
| Average Volume (20 Days) | 113.18K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.86x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.86x |
|---|---|
| Quick Ratio | 2.72x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -1.28% over the last 12 months, against a 5-year average of -17.38%.
| Return on Equity (ROE) | -1.28% |
|---|---|
| Return on Assets (ROA) | -0.93% |
| ROE (5Y Average) | -17.38% |
| ROA (5Y Average) | -13.43% |
| ROIC (5Y Average) | -1.49% |
| Asset Turnover | 0.65x |
| Inventory Turnover | 1.53x |
| Receivables Turnover | 4.63x |
| Cash Conversion Cycle | 267 days |
Scores
ANIK has an Altman Z-Score of 3.51, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.51 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $123.43M over the last 12 months is up 9.42% from the 12 months before.
| Revenue | $123.43M |
|---|---|
| Revenue Growth (YoY) | +9.42% |
| Gross Profit | $78.26M |
| Operating Income | -$2.60M |
| Pretax Income | -$999.00K |
| Net Income | -$1.77M |
| EBITDA | $3.07M |
| Reported EPS (TTM) | $0.69 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.56% of the $189.60M in total assets.
| Cash and Equivalents | $44.96M |
|---|---|
| Total Debt | $0 |
| Net Cash | $44.96M |
| Net Cash Per Share | $3.36 |
| Working Capital | $76.32M |
| Shareholder Equity | $137.58M |
| Book Value Per Share | $10.28 |
| Tangible Book Value | $128.15M |
| Tangible Book Per Share | $9.57 |
| Total Assets | $189.60M |
| Total Liabilities | $52.02M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.19M of capital spending, operating cash flow left $2.29M of free cash flow.
| Operating Cash Flow | $7.48M |
|---|---|
| Capital Expenditures | $5.19M |
| Free Cash Flow | $2.29M |
| FCF Per Share | $0.17 |
| Depreciation and Amortization | $5.67M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2.11%, against a 5-year average of -1.67%.
| Gross Margin | 63.40% |
|---|---|
| Operating Margin | -2.11% |
| Pretax Margin | -0.81% |
| Net Margin | -1.43% |
| EBITDA Margin | 2.49% |
| FCF Margin | 1.86% |
| Gross Margin (5Y Average) | 61.74% |
| Operating Margin (5Y Average) | -1.67% |
| Net Margin (5Y Average) | -27.07% |
Growth
Revenue fell 0.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | -0.30% |
|---|---|
| Revenue Growth (5Y CAGR) | -2.86% |
| FCF Growth (5Y CAGR) | -17.53% |
| Book Value Per Share Growth (2Y CAGR) | -17.85% |
| Tangible Book Per Share Growth (2Y CAGR) | -18.71% |
Dividends and Yields
ANIK does not pay a dividend. Its free cash flow yield is 1.33%.
| Earnings Yield | 5.38% |
|---|---|
| FCF Yield | 1.33% |
| Buyback Yield | 8.61% |
| Shareholder Yield | 8.61% |
Peer Position
Against 9 similar companies, ANIK has the 5th highest P/S.
P/S RatioPeer median 0.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.08%
| P/S Ratio | 1.4x vs 0.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.42% vs +13.08% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.98% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.98% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ANIK
What is ANIK's market cap?
Anika Therapeutics has a market cap of $173.07M. Its enterprise value, which adds debt and subtracts cash, is $128.11M.
What is ANIK's P/E ratio?
Anika Therapeutics has a trailing P/E ratio of 18.6x and a forward P/E of 359.9x.
How many shares of ANIK are outstanding?
Anika Therapeutics has 13.39M shares outstanding. The count is down 7.15% from a year earlier.
Does ANIK pay a dividend?
No. Anika Therapeutics does not pay a dividend.
How much debt does ANIK have?
Anika Therapeutics has $0 of total debt and $44.96M of cash and equivalents, a net cash position of $44.96M.
ANIK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors